The importance of recent ASCO 2025 insights for oncology clinical trial supply
- Clinical Services International (CSI)
- Jun 11
- 2 min read
Updated: Jun 19
ASCO 2025 Signals a New Chapter in Myelofibrosis Care
The 2025 ASCO Annual Meeting delivered early visibility into where the myelofibrosis (MF) pipeline is headed. For Clinical Services International (CSI), a trusted sourcing partner for global oncology trials, this is a scientific milestone.
What’s New in MF and Why It Matters
JAK inhibitors remain foundational, with ruxolitinib holding strong as a first-line option. However, ASCO 2025 spotlighted pacritinib (Vonjo) and momelotinib (Ojjaara) are two agents showing strong performance in thrombocytopenic and anaemic populations, respectively. Their positive Phase 3 and real-world data could accelerate new clinical trial activity as early as Q3 2025.
Also drawing attention: pegylated interferons, especially ropeginterferon alfa-2b, which are gaining traction due to durable molecular responses in younger, mutation-positive patients. Their resurgence signals a diversification of treatment strategies, especially for front-line haematology studies.
CSI has delivered global Phase III registration studies with ruxolitinib and we are ready to do the same with pacritinib (Vonjo) and momelotinib (Ojjaara).
Why CSI Is Watching Closely
1. Demand Forecasting in Real Time
CSI is already preparing for demand in pacritinib, momelotinib and ropeginterferon. All three have limited commercial inventory and narrow sourcing channels, making early action essential. Sponsors with short timelines will need partners who are informed and ready.
2. Strategic Advantage Through Vigilance
By tracking the clinical conversation in real time, CSI positions itself as a highly reliable and informed sourcing partner. Being proactive, rather than reactive, reinforces our value to sponsors navigating fast-changing protocols and regulatory requirements.
3. Opportunity for Thought Leadership
CSI are committed to forward-looking supply planning, particularly in high-complexity areas like hematologic oncology. CSI is tracking the latest data, positioning us as the low-risk sourcing partner for new trials.
Bottom Line
CSI’s ability to connect the dots between clinical data and commercial drug supply is what will continue to set us apart in a rapidly evolving clinical trial supply space.
References:
"ASCO 2025 Delivers Insight into Future of Myelofibrosis Care." Pharmacy Times, 6 June 2025, https://www.pharmacytimes.com/view/asco-2025-delivers-insight-into-future-of-myelofibrosis-care.
.png){kind=logo}
It's exciting to see progress in MF treatment highlighted at ASCO 2025, especially for therapies like pacritinib and momelotinib. As clinical trials expand, securing high-quality clinical trial material supply for oncology drugs will be critical to ensure timelines and regulatory success. Looking forward to seeing how these pipeline advancements translate into real-world impact.
Nucleic acid vaccines were introduced decades ago but have already been widely used in infectious and malignant diseases. Nucleic acid vaccination is a technique for protecting against disease by injection with genetically engineered DNA (as a plasmid) or RNA (as mRNA). In contrast to recombinant bacteria or virus vaccines, nucleic acid vaccines consist only of DNA or RNA, which is uptake by cells and transformed into protein.